Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5219917 | 0.81 | CYP1A2 (0.43) | CYP1A2KDM4EALDH1A1MAPTCYP2C9 | |
| SCHEMBL6053636 | 0.81 | HSD17B10 (0.41) | CYP1A2HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL5221927 | 0.80 | CYP11B2 (0.49) | HPGDKDM4EALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL22939960 | 0.73 | CYP1A2 (0.59) | CYP1A2HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL5217488 | 0.73 | HPGD (0.45) | CYP1A2HPGDKDM4EALDH1A1MAPT | |
| SCHEMBL7603924 | 0.71 | CASR (0.52) | — | |
| SCHEMBL7603925 | 0.71 | CASR (0.52) | — | |
| SCHEMBL7604097 | 0.69 | MGLL (0.48) | — | |
| SCHEMBL7604094 | 0.69 | MGLL (0.48) | — | |
| SCHEMBL10507044 | 0.69 | CYP1A2 (0.68) | CYP1A2HPGDKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368318-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| US-6864267-B2 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1368318-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030212110-A1 | Glandular disorders; bone disorders | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2002007673-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212110-A1 | Glandular disorders; bone disorders | CYP24A1, PTH1R, SOST | CYP1A2 4201/4885HPGD 87/4885KDM4E 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.